8-[(3R)-3-aminopiperidin-1-yl]-7-benzyl-1,3-dimethylpurine-2,6-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 8-[(3R)-3-aminopiperidin-1-yl]-7-benzyl-1,3-dimethylpurine-2,6-dione
• 化学式: C₁₉H₂₄N₆O₂
• 分子量: 368.4
• InChiKey: BLGQZJNVPWQDPL-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  87.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
  申请人：——

  公开号：US20030105077A1

  公开（公告）日：2003-06-05

  The present invention relates to therapeutically active and selective inhibitors of the enzyme DPP-IV of formula I, pharmaceutical compositions comprising the compounds and the use of such compounds for and the manufacture of medicaments for treating diseases that are associated with proteins that are subject to inactivation by DPP-IV, such as type 2 diabetes and obesity. 1

  本发明涉及公式I的治疗活性和选择性DPP-IV酶抑制剂，包括该化合物的药物组合物以及利用这些化合物制备用于治疗受DPP-IV失活蛋白质相关的疾病的药物，如2型糖尿病和肥胖症。
• Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
  申请人：Keto Patent Group, Inc.

  公开号：US11173138B2

  公开（公告）日：2021-11-16

  In various implementations, beta-hydroxybutyrate, related compounds, and/or one or more other compounds may be administered to an individual to cause weight loss, weight maintenance, elevate blood ketone levels, maintain blood ketone levels, reduce blood glucose levels, maintain blood glucose levels, improve energy, focus, mood, cognitive function, or aide with neurological or inflammatory disorders and/or combinations thereof. Other compounds may include short chain fatty acids, short chain triglycerides, medium chain fatty acids, medium chain triglycerides, long chain fatty acids, long chain triglycerides, berberine, metabolites of berberine (e.g., dihydroberberine), and/or combinations thereof.

  在各种实施方案中，β-羟基丁酸盐、相关化合物和/或一种或多种其他化合物可被施用于个体，以减轻体重、维持体重、提高血酮水平、维持血酮水平、降低血糖水平、维持血糖水平、改善能量、注意力、情绪、认知功能或辅助治疗神经或炎症性疾病和/或其组合。 其他化合物可包括短链脂肪酸、短链甘油三酯、中链脂肪酸、中链甘油三酯、长链脂肪酸、长链甘油三酯、小檗碱、小檗碱的代谢物（如二氢小檗碱）和/或其组合。
• DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES
  申请人：NOVO NORDISK A/S

  公开号：EP1404675A1

  公开（公告）日：2004-04-07
• ADMINISTRATION OF BUTYRATE, BETE-HYDROXYBUTYRATE, CANNABIDIOL, AND RELATED COMPOUNDS IN HUMANS
  申请人：Keto Patent Group, Inc.

  公开号：EP3873442A1

  公开（公告）日：2021-09-08
• ADMINISTRATION OF BUTYRATE, BETA-HYDROXYBUTYRATE, AND RELATED COMPOUNDS IN HUMANS
  申请人：Keto Patent Group, Inc.

  公开号：US20170296501A1

  公开（公告）日：2017-10-19

  In various implementations, beta-hydroxybutyrate, related compounds, and/or one or more other compounds may be administered to an individual to cause weight loss, weight maintenance, elevate blood ketone levels, maintain blood ketone levels, reduce blood glucose levels, maintain blood glucose levels, improve energy, focus, mood, cognitive function, or aide with neurological or inflammatory disorders and/or combinations thereof. Other compounds may include short chain fatty acids, short chain triglycerides, medium chain fatty acids, medium chain triglycerides, long chain fatty acids, long chain triglycerides, berberine, metabolites of berberine (e.g., dihydroberberine), and/or combinations thereof.